<SEC-DOCUMENT>0001193125-19-160233.txt : 20190530
<SEC-HEADER>0001193125-19-160233.hdr.sgml : 20190530
<ACCEPTANCE-DATETIME>20190530072155
ACCESSION NUMBER:		0001193125-19-160233
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190530
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190530
DATE AS OF CHANGE:		20190530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZAFGEN, INC.
		CENTRAL INDEX KEY:			0001374690
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203857670
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36510
		FILM NUMBER:		19864570

	BUSINESS ADDRESS:	
		STREET 1:		175 PORTLAND STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114
		BUSINESS PHONE:		617-622-4003

	MAIL ADDRESS:	
		STREET 1:		175 PORTLAND STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN INC
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d747725d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;30, 2019 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Zafgen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36510</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-3857670</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>175 Portland Street, 4th Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02114</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code
<FONT STYLE="white-space:nowrap">(617)&nbsp;622-4003</FONT> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>ZFGN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>NASDAQ Global Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;30, 2019, Zafgen, Inc. (the &#147;Company&#148;) issued a press release announcing a regulatory update on
<FONT STYLE="white-space:nowrap">ZGN-1061.</FONT> A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and Exhibit 99.1 attached hereto is intended to be furnished and shall not
be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d747725dex991.htm">Press release issued by Zafgen, Inc. on May&nbsp;30, 2019, furnished herewith. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;30, 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ZAFGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey Hatfield</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeffrey Hatfield</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d747725dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g747725g0530022239625.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zafgen Announces Regulatory Update on <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Received FDA Type A meeting minutes related to previously announced clinical hold </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>FDA acknowledged newly developed </I>in vitro<I> assays of human plasma coagulation and tissue factor expression</I><I> </I><I>qualitatively
differentiate <FONT STYLE="white-space:nowrap">ZGN-1061</FONT></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company is working with FDA to translate in vitro data and confirm
relevant safety margins in an in vivo model </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Additionally, Zafgen is exploring a second IND for
<FONT STYLE="white-space:nowrap">ZGN-1061</FONT> in a population with higher unmet medical need </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boston, Mass., May</B><B></B><B>&nbsp;30, 2019</B>
&#150; Zafgen, Inc.&nbsp;(Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced the
receipt of minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical hold for <FONT STYLE="white-space:nowrap">ZGN-1061.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen provided key new data in advance of the meeting, including newly developed<I>&nbsp;in vitro</I>&nbsp;assays of human plasma coagulation using
endothelial cells and assessment of tissue factor expression with endothelial cells, and other supportive new assays. The Company is working with FDA to gain alignment on an <I>in vivo</I> animal model to confirm relevant safety margins as a next
step toward resolving the clinical hold. Zafgen will be prepared to rapidly implement the agreed upon work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Type A meeting with the FDA for <FONT
STYLE="white-space:nowrap">ZGN-1061</FONT> was marked by constructive dialogue and progress driven by the important new data that the team worked diligently to provide to inform the discussion. This effort for Zafgen was led by highly experienced
members of our team, Dr.&nbsp;Priya Singhal, our new Head of R&amp;D, and Lisa Percival, our Vice President of Regulatory,&#148; said Jeffrey Hatfield, Chief Executive Officer. &#147;We believe the new <I>in vitro</I> data generated was encouraging,
and the FDA was helpful with guidance regarding data needed to move forward in type 2 diabetes.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company is evaluating serious,
rare disease indications that have few or no approved therapies in which <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> could potentially benefit patients. The FDA was supportive of Zafgen seeking guidance on a second investigational new drug
application (IND) for <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> as appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen will provide an update on development plans by the end of the third quarter of 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Zafgen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen (Nasdaq:ZFGN) is a
clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare
metabolic disorders. Learn more at www.zafgen.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements in this release concerning&nbsp;Zafgen&#146;s&nbsp;future expectations, plans and prospects, including without
limitation,&nbsp;Zafgen&#146;s&nbsp;expectations regarding the development and use of ZGN-1061 as a treatment for metabolic diseases, nonclinical or clinical options to resolve the clinical hold concerning
<FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> and&nbsp;Zafgen&#146;s&nbsp;expectations with respect to the timing and success of its nonclinical studies and clinical trials of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> and its other
product candidates, and Zafgen&#146;s expectations regarding the length of its cash runway, may constitute forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Forward-looking statements can be identified by terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;could increase the likelihood,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;is planned,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;will enable,&#148; &#147;would be expected,&#148; &#147;look forward,&#148; &#147;may provide,&#148; &#147;would&#148; or similar terms,
variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without
limitation,&nbsp;Zafgen&#146;s&nbsp;ability to successfully demonstrate the efficacy and safety of <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> <FONT STYLE="white-space:nowrap">ZGN-1258,</FONT> <FONT STYLE="white-space:nowrap">ZGN-1345</FONT>
and its other product candidates and to differentiate them from first generation MetAP2 inhibitors, such as beloranib, the nonclinical and clinical results for <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT>
<FONT STYLE="white-space:nowrap">ZGN-1258,</FONT> <FONT STYLE="white-space:nowrap">ZGN-1345</FONT> and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect
the initiation, timing and progress of nonclinical studies and clinical trials of its product candidates,&nbsp;Zafgen&#146;s ability to successfully engage with the FDA concerning the clinical hold on a clinical trial of <FONT
STYLE="white-space:nowrap">ZGN-1061</FONT> and to design and conduct a nonclinical study or clinical trial demonstrating sufficient data to exclude cardiovascular risk to an acceptable degree and demonstrating the risk is reasonable to type 2
diabetes or other indications, Zafgen&#146;s ability to overcome the full clinical hold placed on <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> by the FDA and obtain regulatory approval, Zafgen&#146;s ability to continue to evaluate <FONT
STYLE="white-space:nowrap">ZGN-1258</FONT> and to advance the program in nonclinical and clinical development, Zafgen&#146;s&nbsp;ability to obtain, maintain and protect its intellectual property,&nbsp;Zafgen&#146;s&nbsp;ability to enforce its
patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen&#146;s ability to manage operating expenses,&nbsp;Zafgen&#146;s&nbsp;ability to
obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives when needed,&nbsp;Zafgen&#146;s ability to attract and retain personnel, Zafgen&#146;s&nbsp;dependence
on third parties for development, manufacture, marketing, sales and distribution of product candidates, and unexpected expenditures, as well as those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
risks more fully discussed in the section entitled &#147;Risk Factors&#148; in&nbsp;Zafgen&#146;s&nbsp;most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with
the&nbsp;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in&nbsp;Zafgen&#146;s&nbsp;subsequent filings with the&nbsp;Securities and Exchange Commission, including without
limitation Zafgen&#146;s Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> In addition, any forward-looking statements represent&nbsp;Zafgen&#146;s&nbsp;views only as of today and should not be relied upon as representing its
views as of any subsequent date.&nbsp;Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media/Investor Relations Contacts</B>: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patricia Allen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-648-9792</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Krystle Gibbs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">krystle@tenbridgecommunications.com
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">508-479-6358</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investors </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Woolford </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>john.woolford@westwicke.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-213-0506</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g747725g0530022239625.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g747725g0530022239625.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ -4# 2(  A$! Q$!_\0
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M_$=]/?:H-,@)V*P7:#]]CZ_2KT'@VV$(^T7$C2$<[. #67:?/XU)(_Y>'/\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
